The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
Exploring the latest breakthroughs in partial reprogramming using OSKM factors for anti-aging, with insights from mouse studies and early clinical trials for eye diseases. Recent studies show partial ...
Recent studies show encapsulated mitochondria delivery using red blood cell membranes improves motor function and neuron survival in Parkinson’s disease models, offering hope for mitochondrial d...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Recent UK Biobank data reveals myostatin variants boosting muscle mass, with research accelerating on combining inhibitors with GLP-1 drugs to combat sarcopenia, highlighting ethical debates in therap...
Exploring recent advances in senolytic and senomorphic therapies, including dasatinib-quercetin and immune-based approaches, to combat age-related diseases like Alzheimer’s and sarcopenia. New t...
Recent studies reveal that supplementing Roseburia inulinivorans enhances muscle strength by up to 30% in mice, with human trials showing promise for probiotic therapies against sarcopenia. New resear...